nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—CYP3A4—bone cancer	0.794	1	CbGaD
Dihydroergotamine—HTR1B—dura mater—bone cancer	0.0266	0.27	CbGeAlD
Dihydroergotamine—HTR1D—dura mater—bone cancer	0.0257	0.261	CbGeAlD
Dihydroergotamine—HTR1B—trigeminal nerve—bone cancer	0.0114	0.116	CbGeAlD
Dihydroergotamine—HTR1D—trigeminal nerve—bone cancer	0.0111	0.112	CbGeAlD
Dihydroergotamine—HTR1B—cranial nerve—bone cancer	0.00814	0.0827	CbGeAlD
Dihydroergotamine—HTR1D—cranial nerve—bone cancer	0.00788	0.0801	CbGeAlD
Dihydroergotamine—Ergoloid mesylate—CYP3A4—bone cancer	0.00347	0.566	CrCbGaD
Dihydroergotamine—HTR1D—connective tissue—bone cancer	0.00163	0.0165	CbGeAlD
Dihydroergotamine—Ergotamine—CYP3A4—bone cancer	0.00136	0.221	CrCbGaD
Dihydroergotamine—Bromocriptine—CYP3A4—bone cancer	0.00131	0.213	CrCbGaD
Dihydroergotamine—HTR1B—spinal cord—bone cancer	0.00111	0.0113	CbGeAlD
Dihydroergotamine—HTR2B—tendon—bone cancer	0.00104	0.0106	CbGeAlD
Dihydroergotamine—ADRA2A—connective tissue—bone cancer	0.00095	0.00965	CbGeAlD
Dihydroergotamine—HTR1A—spinal cord—bone cancer	0.000899	0.00913	CbGeAlD
Dihydroergotamine—Petechiae—Methotrexate—bone cancer	0.000864	0.00857	CcSEcCtD
Dihydroergotamine—Cramp muscle—Cisplatin—bone cancer	0.000847	0.0084	CcSEcCtD
Dihydroergotamine—Speech disorder—Methotrexate—bone cancer	0.000827	0.0082	CcSEcCtD
Dihydroergotamine—Rigors—Epirubicin—bone cancer	0.000815	0.00808	CcSEcCtD
Dihydroergotamine—Petechiae—Epirubicin—bone cancer	0.000809	0.00802	CcSEcCtD
Dihydroergotamine—Musculoskeletal stiffness—Methotrexate—bone cancer	0.000793	0.00786	CcSEcCtD
Dihydroergotamine—Sweating increased—Cisplatin—bone cancer	0.000792	0.00785	CcSEcCtD
Dihydroergotamine—Herpes simplex—Methotrexate—bone cancer	0.000771	0.00765	CcSEcCtD
Dihydroergotamine—Rigors—Doxorubicin—bone cancer	0.000754	0.00748	CcSEcCtD
Dihydroergotamine—Petechiae—Doxorubicin—bone cancer	0.000748	0.00742	CcSEcCtD
Dihydroergotamine—Herpes simplex—Epirubicin—bone cancer	0.000722	0.00716	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Cisplatin—bone cancer	0.000714	0.00708	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Methotrexate—bone cancer	0.000711	0.00705	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Cisplatin—bone cancer	0.00071	0.00704	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Cisplatin—bone cancer	0.000705	0.00698	CcSEcCtD
Dihydroergotamine—Cystitis noninfective—Methotrexate—bone cancer	0.000694	0.00689	CcSEcCtD
Dihydroergotamine—Cystitis—Methotrexate—bone cancer	0.000687	0.00681	CcSEcCtD
Dihydroergotamine—Depressed level of consciousness—Methotrexate—bone cancer	0.000687	0.00681	CcSEcCtD
Dihydroergotamine—Gait disturbance—Epirubicin—bone cancer	0.000682	0.00676	CcSEcCtD
Dihydroergotamine—Vaginal infection—Methotrexate—bone cancer	0.000671	0.00665	CcSEcCtD
Dihydroergotamine—Herpes simplex—Doxorubicin—bone cancer	0.000668	0.00662	CcSEcCtD
Dihydroergotamine—Hiccups—Epirubicin—bone cancer	0.000665	0.0066	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Epirubicin—bone cancer	0.000665	0.0066	CcSEcCtD
Dihydroergotamine—Ventricular tachycardia—Epirubicin—bone cancer	0.000665	0.0066	CcSEcCtD
Dihydroergotamine—ADRA2A—tendon—bone cancer	0.000653	0.00664	CbGeAlD
Dihydroergotamine—Cystitis noninfective—Epirubicin—bone cancer	0.00065	0.00644	CcSEcCtD
Dihydroergotamine—Salivary hypersecretion—Epirubicin—bone cancer	0.000646	0.00641	CcSEcCtD
Dihydroergotamine—Influenza like illness—Epirubicin—bone cancer	0.000646	0.00641	CcSEcCtD
Dihydroergotamine—Bladder pain—Methotrexate—bone cancer	0.000643	0.00637	CcSEcCtD
Dihydroergotamine—Cystitis—Epirubicin—bone cancer	0.000642	0.00637	CcSEcCtD
Dihydroergotamine—Gait disturbance—Doxorubicin—bone cancer	0.000631	0.00625	CcSEcCtD
Dihydroergotamine—ADRA2A—spinal cord—bone cancer	0.00063	0.0064	CbGeAlD
Dihydroergotamine—Vaginal infection—Epirubicin—bone cancer	0.000628	0.00623	CcSEcCtD
Dihydroergotamine—Visual impairment—Cisplatin—bone cancer	0.000627	0.00622	CcSEcCtD
Dihydroergotamine—Ventricular tachycardia—Doxorubicin—bone cancer	0.000616	0.0061	CcSEcCtD
Dihydroergotamine—Hiccups—Doxorubicin—bone cancer	0.000616	0.0061	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Doxorubicin—bone cancer	0.000616	0.0061	CcSEcCtD
Dihydroergotamine—Tinnitus—Cisplatin—bone cancer	0.000607	0.00601	CcSEcCtD
Dihydroergotamine—Flushing—Cisplatin—bone cancer	0.000604	0.00599	CcSEcCtD
Dihydroergotamine—Bladder pain—Epirubicin—bone cancer	0.000602	0.00596	CcSEcCtD
Dihydroergotamine—Cystitis noninfective—Doxorubicin—bone cancer	0.000601	0.00596	CcSEcCtD
Dihydroergotamine—Influenza like illness—Doxorubicin—bone cancer	0.000598	0.00593	CcSEcCtD
Dihydroergotamine—Salivary hypersecretion—Doxorubicin—bone cancer	0.000598	0.00593	CcSEcCtD
Dihydroergotamine—Cystitis—Doxorubicin—bone cancer	0.000594	0.00589	CcSEcCtD
Dihydroergotamine—Vaginal infection—Doxorubicin—bone cancer	0.000581	0.00576	CcSEcCtD
Dihydroergotamine—Abnormal vision—Epirubicin—bone cancer	0.00058	0.00575	CcSEcCtD
Dihydroergotamine—Mental disability—Epirubicin—bone cancer	0.000577	0.00572	CcSEcCtD
Dihydroergotamine—Bladder pain—Doxorubicin—bone cancer	0.000557	0.00552	CcSEcCtD
Dihydroergotamine—Muscle spasms—Cisplatin—bone cancer	0.000545	0.0054	CcSEcCtD
Dihydroergotamine—Abnormal vision—Doxorubicin—bone cancer	0.000537	0.00532	CcSEcCtD
Dihydroergotamine—Eye pain—Epirubicin—bone cancer	0.000535	0.0053	CcSEcCtD
Dihydroergotamine—Mental disability—Doxorubicin—bone cancer	0.000534	0.0053	CcSEcCtD
Dihydroergotamine—Tremor—Cisplatin—bone cancer	0.000531	0.00526	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Methotrexate—bone cancer	0.000527	0.00522	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Cisplatin—bone cancer	0.000526	0.00521	CcSEcCtD
Dihydroergotamine—Hot flush—Epirubicin—bone cancer	0.000516	0.00512	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Epirubicin—bone cancer	0.000512	0.00507	CcSEcCtD
Dihydroergotamine—Malaise—Cisplatin—bone cancer	0.000511	0.00506	CcSEcCtD
Dihydroergotamine—Eye pain—Doxorubicin—bone cancer	0.000495	0.00491	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Epirubicin—bone cancer	0.000493	0.00489	CcSEcCtD
Dihydroergotamine—Myalgia—Cisplatin—bone cancer	0.000482	0.00478	CcSEcCtD
Dihydroergotamine—Anxiety—Cisplatin—bone cancer	0.000481	0.00476	CcSEcCtD
Dihydroergotamine—Hot flush—Doxorubicin—bone cancer	0.000478	0.00474	CcSEcCtD
Dihydroergotamine—Discomfort—Cisplatin—bone cancer	0.000476	0.00472	CcSEcCtD
Dihydroergotamine—Migraine—Epirubicin—bone cancer	0.000475	0.00471	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Doxorubicin—bone cancer	0.000474	0.0047	CcSEcCtD
Dihydroergotamine—Face oedema—Epirubicin—bone cancer	0.000466	0.00462	CcSEcCtD
Dihydroergotamine—Oedema—Cisplatin—bone cancer	0.000462	0.00458	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Doxorubicin—bone cancer	0.000456	0.00452	CcSEcCtD
Dihydroergotamine—Tachycardia—Cisplatin—bone cancer	0.000451	0.00447	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Cisplatin—bone cancer	0.000447	0.00443	CcSEcCtD
Dihydroergotamine—Anorexia—Cisplatin—bone cancer	0.000441	0.00437	CcSEcCtD
Dihydroergotamine—Migraine—Doxorubicin—bone cancer	0.00044	0.00436	CcSEcCtD
Dihydroergotamine—Hypotension—Cisplatin—bone cancer	0.000432	0.00428	CcSEcCtD
Dihydroergotamine—Face oedema—Doxorubicin—bone cancer	0.000431	0.00428	CcSEcCtD
Dihydroergotamine—Muscular weakness—Epirubicin—bone cancer	0.000426	0.00422	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000421	0.00418	CcSEcCtD
Dihydroergotamine—Dysphagia—Epirubicin—bone cancer	0.000417	0.00414	CcSEcCtD
Dihydroergotamine—Paraesthesia—Cisplatin—bone cancer	0.000415	0.00412	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Methotrexate—bone cancer	0.000415	0.00411	CcSEcCtD
Dihydroergotamine—Dyspnoea—Cisplatin—bone cancer	0.000412	0.00409	CcSEcCtD
Dihydroergotamine—Angina pectoris—Epirubicin—bone cancer	0.000407	0.00403	CcSEcCtD
Dihydroergotamine—Decreased appetite—Cisplatin—bone cancer	0.000402	0.00398	CcSEcCtD
Dihydroergotamine—Bronchitis—Epirubicin—bone cancer	0.000401	0.00398	CcSEcCtD
Dihydroergotamine—Pain—Cisplatin—bone cancer	0.000395	0.00392	CcSEcCtD
Dihydroergotamine—Muscular weakness—Doxorubicin—bone cancer	0.000394	0.00391	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Epirubicin—bone cancer	0.000388	0.00385	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Methotrexate—bone cancer	0.000387	0.00383	CcSEcCtD
Dihydroergotamine—Dysphagia—Doxorubicin—bone cancer	0.000386	0.00383	CcSEcCtD
Dihydroergotamine—Pollakiuria—Epirubicin—bone cancer	0.000386	0.00382	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Cisplatin—bone cancer	0.000381	0.00378	CcSEcCtD
Dihydroergotamine—Angina pectoris—Doxorubicin—bone cancer	0.000376	0.00373	CcSEcCtD
Dihydroergotamine—Epistaxis—Methotrexate—bone cancer	0.000375	0.00372	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—bone cancer	0.000371	0.00368	CcSEcCtD
Dihydroergotamine—Body temperature increased—Cisplatin—bone cancer	0.000365	0.00362	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Epirubicin—bone cancer	0.000362	0.00359	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000359	0.00356	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—bone cancer	0.000357	0.00354	CcSEcCtD
Dihydroergotamine—Pharyngitis—Methotrexate—bone cancer	0.000354	0.00351	CcSEcCtD
Dihydroergotamine—ABCB1—bone marrow—bone cancer	0.000353	0.00358	CbGeAlD
Dihydroergotamine—ABCB1—spinal cord—bone cancer	0.000351	0.00357	CbGeAlD
Dihydroergotamine—Epistaxis—Epirubicin—bone cancer	0.000351	0.00348	CcSEcCtD
Dihydroergotamine—Sinusitis—Epirubicin—bone cancer	0.000349	0.00346	CcSEcCtD
Dihydroergotamine—Visual impairment—Methotrexate—bone cancer	0.000344	0.00341	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Cisplatin—bone cancer	0.000341	0.00338	CcSEcCtD
Dihydroergotamine—Rhinitis—Epirubicin—bone cancer	0.000335	0.00332	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—bone cancer	0.000335	0.00332	CcSEcCtD
Dihydroergotamine—Tinnitus—Methotrexate—bone cancer	0.000333	0.0033	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Epirubicin—bone cancer	0.000332	0.0033	CcSEcCtD
Dihydroergotamine—Asthenia—Cisplatin—bone cancer	0.000332	0.00329	CcSEcCtD
Dihydroergotamine—Pharyngitis—Epirubicin—bone cancer	0.000332	0.00329	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—bone cancer	0.000325	0.00322	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—bone cancer	0.000323	0.0032	CcSEcCtD
Dihydroergotamine—Visual impairment—Epirubicin—bone cancer	0.000322	0.00319	CcSEcCtD
Dihydroergotamine—Chills—Methotrexate—bone cancer	0.00032	0.00318	CcSEcCtD
Dihydroergotamine—Diarrhoea—Cisplatin—bone cancer	0.000316	0.00314	CcSEcCtD
Dihydroergotamine—Tinnitus—Epirubicin—bone cancer	0.000312	0.00309	CcSEcCtD
Dihydroergotamine—Flushing—Epirubicin—bone cancer	0.00031	0.00307	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—bone cancer	0.00031	0.00307	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—bone cancer	0.000308	0.00305	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—bone cancer	0.000307	0.00304	CcSEcCtD
Dihydroergotamine—Chills—Epirubicin—bone cancer	0.0003	0.00297	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—bone cancer	0.000298	0.00295	CcSEcCtD
Dihydroergotamine—Vomiting—Cisplatin—bone cancer	0.000294	0.00291	CcSEcCtD
Dihydroergotamine—Rash—Cisplatin—bone cancer	0.000291	0.00289	CcSEcCtD
Dihydroergotamine—Dermatitis—Cisplatin—bone cancer	0.000291	0.00289	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methotrexate—bone cancer	0.000288	0.00286	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—bone cancer	0.000288	0.00286	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—bone cancer	0.000287	0.00284	CcSEcCtD
Dihydroergotamine—Tension—Epirubicin—bone cancer	0.000285	0.00283	CcSEcCtD
Dihydroergotamine—Nervousness—Epirubicin—bone cancer	0.000282	0.0028	CcSEcCtD
Dihydroergotamine—Malaise—Methotrexate—bone cancer	0.00028	0.00278	CcSEcCtD
Dihydroergotamine—Muscle spasms—Epirubicin—bone cancer	0.00028	0.00277	CcSEcCtD
Dihydroergotamine—Vertigo—Methotrexate—bone cancer	0.000279	0.00277	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—bone cancer	0.000277	0.00275	CcSEcCtD
Dihydroergotamine—Nausea—Cisplatin—bone cancer	0.000275	0.00272	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Epirubicin—bone cancer	0.00027	0.00268	CcSEcCtD
Dihydroergotamine—Agitation—Epirubicin—bone cancer	0.000267	0.00265	CcSEcCtD
Dihydroergotamine—Myalgia—Methotrexate—bone cancer	0.000265	0.00262	CcSEcCtD
Dihydroergotamine—Arthralgia—Methotrexate—bone cancer	0.000265	0.00262	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—bone cancer	0.000264	0.00262	CcSEcCtD
Dihydroergotamine—Malaise—Epirubicin—bone cancer	0.000262	0.0026	CcSEcCtD
Dihydroergotamine—Discomfort—Methotrexate—bone cancer	0.000261	0.00259	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—bone cancer	0.000261	0.00259	CcSEcCtD
Dihydroergotamine—Vertigo—Epirubicin—bone cancer	0.000261	0.00259	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—bone cancer	0.000259	0.00257	CcSEcCtD
Dihydroergotamine—Palpitations—Epirubicin—bone cancer	0.000257	0.00255	CcSEcCtD
Dihydroergotamine—Confusional state—Methotrexate—bone cancer	0.000256	0.00254	CcSEcCtD
Dihydroergotamine—Hypertension—Epirubicin—bone cancer	0.000251	0.00249	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—bone cancer	0.00025	0.00248	CcSEcCtD
Dihydroergotamine—Myalgia—Epirubicin—bone cancer	0.000248	0.00245	CcSEcCtD
Dihydroergotamine—Arthralgia—Epirubicin—bone cancer	0.000248	0.00245	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—bone cancer	0.000247	0.00245	CcSEcCtD
Dihydroergotamine—Anxiety—Epirubicin—bone cancer	0.000247	0.00245	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methotrexate—bone cancer	0.000245	0.00243	CcSEcCtD
Dihydroergotamine—Discomfort—Epirubicin—bone cancer	0.000245	0.00243	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—bone cancer	0.000243	0.00241	CcSEcCtD
Dihydroergotamine—Dry mouth—Epirubicin—bone cancer	0.000242	0.0024	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—bone cancer	0.000242	0.0024	CcSEcCtD
Dihydroergotamine—Anorexia—Methotrexate—bone cancer	0.000242	0.0024	CcSEcCtD
Dihydroergotamine—Confusional state—Epirubicin—bone cancer	0.000239	0.00237	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—bone cancer	0.000238	0.00236	CcSEcCtD
Dihydroergotamine—Oedema—Epirubicin—bone cancer	0.000237	0.00235	CcSEcCtD
Dihydroergotamine—Hypotension—Methotrexate—bone cancer	0.000237	0.00235	CcSEcCtD
Dihydroergotamine—Shock—Epirubicin—bone cancer	0.000234	0.00232	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—bone cancer	0.000232	0.0023	CcSEcCtD
Dihydroergotamine—Tachycardia—Epirubicin—bone cancer	0.000232	0.0023	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000231	0.00229	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Epirubicin—bone cancer	0.000229	0.00228	CcSEcCtD
Dihydroergotamine—Insomnia—Methotrexate—bone cancer	0.000229	0.00227	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—bone cancer	0.000229	0.00227	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—bone cancer	0.000229	0.00227	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—bone cancer	0.000228	0.00226	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methotrexate—bone cancer	0.000228	0.00226	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—bone cancer	0.000226	0.00224	CcSEcCtD
Dihydroergotamine—Anorexia—Epirubicin—bone cancer	0.000226	0.00224	CcSEcCtD
Dihydroergotamine—Dyspnoea—Methotrexate—bone cancer	0.000226	0.00224	CcSEcCtD
Dihydroergotamine—Somnolence—Methotrexate—bone cancer	0.000226	0.00224	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—bone cancer	0.000224	0.00222	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methotrexate—bone cancer	0.000223	0.00221	CcSEcCtD
Dihydroergotamine—Hypotension—Epirubicin—bone cancer	0.000222	0.0022	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—bone cancer	0.000221	0.0022	CcSEcCtD
Dihydroergotamine—Decreased appetite—Methotrexate—bone cancer	0.000221	0.00219	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—bone cancer	0.00022	0.00218	CcSEcCtD
Dihydroergotamine—Fatigue—Methotrexate—bone cancer	0.000219	0.00217	CcSEcCtD
Dihydroergotamine—Pain—Methotrexate—bone cancer	0.000217	0.00215	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000216	0.00214	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—bone cancer	0.000216	0.00214	CcSEcCtD
Dihydroergotamine—Insomnia—Epirubicin—bone cancer	0.000215	0.00213	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—bone cancer	0.000214	0.00213	CcSEcCtD
Dihydroergotamine—Paraesthesia—Epirubicin—bone cancer	0.000213	0.00211	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—bone cancer	0.000212	0.00211	CcSEcCtD
Dihydroergotamine—Dyspnoea—Epirubicin—bone cancer	0.000212	0.0021	CcSEcCtD
Dihydroergotamine—Somnolence—Epirubicin—bone cancer	0.000211	0.00209	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—bone cancer	0.000209	0.00208	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methotrexate—bone cancer	0.000209	0.00207	CcSEcCtD
Dihydroergotamine—Dyspepsia—Epirubicin—bone cancer	0.000209	0.00207	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methotrexate—bone cancer	0.000207	0.00206	CcSEcCtD
Dihydroergotamine—Decreased appetite—Epirubicin—bone cancer	0.000206	0.00205	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—bone cancer	0.000205	0.00203	CcSEcCtD
Dihydroergotamine—Fatigue—Epirubicin—bone cancer	0.000205	0.00203	CcSEcCtD
Dihydroergotamine—Pain—Epirubicin—bone cancer	0.000203	0.00201	CcSEcCtD
Dihydroergotamine—Urticaria—Methotrexate—bone cancer	0.000202	0.002	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methotrexate—bone cancer	0.000201	0.00199	CcSEcCtD
Dihydroergotamine—Body temperature increased—Methotrexate—bone cancer	0.000201	0.00199	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.0002	0.00198	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—bone cancer	0.000199	0.00197	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—bone cancer	0.000197	0.00196	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—bone cancer	0.000196	0.00194	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Epirubicin—bone cancer	0.000196	0.00194	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—bone cancer	0.000195	0.00194	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Epirubicin—bone cancer	0.000194	0.00192	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—bone cancer	0.000193	0.00192	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—bone cancer	0.000191	0.00189	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—bone cancer	0.000189	0.00188	CcSEcCtD
Dihydroergotamine—Urticaria—Epirubicin—bone cancer	0.000189	0.00187	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—bone cancer	0.000188	0.00186	CcSEcCtD
Dihydroergotamine—Abdominal pain—Epirubicin—bone cancer	0.000188	0.00186	CcSEcCtD
Dihydroergotamine—Body temperature increased—Epirubicin—bone cancer	0.000188	0.00186	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methotrexate—bone cancer	0.000187	0.00185	CcSEcCtD
Dihydroergotamine—Asthenia—Methotrexate—bone cancer	0.000182	0.0018	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—bone cancer	0.000181	0.00179	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—bone cancer	0.00018	0.00178	CcSEcCtD
Dihydroergotamine—Pruritus—Methotrexate—bone cancer	0.000179	0.00178	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Epirubicin—bone cancer	0.000175	0.00173	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—bone cancer	0.000174	0.00173	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—bone cancer	0.000174	0.00172	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—bone cancer	0.000174	0.00172	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methotrexate—bone cancer	0.000174	0.00172	CcSEcCtD
Dihydroergotamine—Asthenia—Epirubicin—bone cancer	0.00017	0.00169	CcSEcCtD
Dihydroergotamine—Pruritus—Epirubicin—bone cancer	0.000168	0.00167	CcSEcCtD
Dihydroergotamine—Dizziness—Methotrexate—bone cancer	0.000168	0.00166	CcSEcCtD
Dihydroergotamine—Diarrhoea—Epirubicin—bone cancer	0.000162	0.00161	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—bone cancer	0.000162	0.0016	CcSEcCtD
Dihydroergotamine—Vomiting—Methotrexate—bone cancer	0.000161	0.0016	CcSEcCtD
Dihydroergotamine—Rash—Methotrexate—bone cancer	0.00016	0.00159	CcSEcCtD
Dihydroergotamine—Dermatitis—Methotrexate—bone cancer	0.00016	0.00158	CcSEcCtD
Dihydroergotamine—Headache—Methotrexate—bone cancer	0.000159	0.00158	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—bone cancer	0.000158	0.00156	CcSEcCtD
Dihydroergotamine—Dizziness—Epirubicin—bone cancer	0.000157	0.00156	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—bone cancer	0.000155	0.00154	CcSEcCtD
Dihydroergotamine—Vomiting—Epirubicin—bone cancer	0.000151	0.0015	CcSEcCtD
Dihydroergotamine—Nausea—Methotrexate—bone cancer	0.000151	0.00149	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—bone cancer	0.00015	0.00149	CcSEcCtD
Dihydroergotamine—Rash—Epirubicin—bone cancer	0.00015	0.00148	CcSEcCtD
Dihydroergotamine—Dermatitis—Epirubicin—bone cancer	0.00015	0.00148	CcSEcCtD
Dihydroergotamine—Headache—Epirubicin—bone cancer	0.000149	0.00147	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—bone cancer	0.000145	0.00144	CcSEcCtD
Dihydroergotamine—Nausea—Epirubicin—bone cancer	0.000141	0.0014	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—bone cancer	0.00014	0.00138	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—bone cancer	0.000138	0.00137	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—bone cancer	0.000138	0.00137	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—bone cancer	0.000138	0.00136	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—bone cancer	0.00013	0.00129	CcSEcCtD
